Safety and Tolerability of AZD6482 in Reperfusion for Stroke
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
STARS is a prospective, multicentre, open-label, dose escalation, Phase IIa study to assess
the safety and tolerability of AZD6482, an adjuvant antiplatelet therapy, in patients with
AIS.
Acute ischaemic stroke (AIS) is caused by a severe blockage of an artery leading to immediate
reduced blood flow to part of the brain. Standard therapies target the blocked artery by
either dissolving the blockage or removing the blockage. However, even after successful
treatment, re-blockage of arteries can occur. The use of an antiplatelet therapy, AZD6482, in
addition to standard therapies offers the possibility of improved restoration of blood flow
and reduced rates of artery re-blockage.